TapewireFind a company

person · Reporting owner

Miller Mary

Disclosed activity across 2 companies

Tapewire entity
21132
SEC CIK
0001841088

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Acrivon Therapeutics, Inc.ACRV · Entity 573Chief Legal OfficerOctober 05, 2026October 07, 2026
Butterfly Network, Inc.BFLY · Entity 4467General Counsel & Corp SecMarch 22, 2022March 24, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Acrivon Therapeutics, Inc.

Report date October 05, 2026 · Filed October 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect81,715 Reported balance After 2026-10-05 transaction · row 1
1 source row

Row 1 · 2026-10-05 · Sale · Disposed 294 · Balance 81,715

F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

F2: The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

F2: The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.

Butterfly Network, Inc.

Report date March 22, 2022 · Filed March 24, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect383,512 Reported balance After 2022-03-22 transaction · row 1
1 source row

Row 1 · 2022-03-22 · Grant · Acquired 54,789 · Balance 383,512

F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 22, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 22, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 05, 2026 Filed Oct 7, 2026 21:02 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 SaleCommon Stock 294 $1.99 $585.06
Disclosure

SEC source: 0000905148-26-004399 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,715

F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

F2 · price: The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.

Read SEC document
August 18, 2026 Filed Aug 20, 2026 20:09 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 SaleCommon Stock 185 $2.01 $371.85
Disclosure

SEC source: 0000905148-26-003839 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,009

F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
July 21, 2026 Filed Jul 23, 2026 20:28 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 SaleCommon Stock 573 $1.76 $1,008.48
Disclosure

SEC source: 0000905148-26-003334 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,194

F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
May 18, 2026 Filed May 20, 2026 20:30 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 GrantCommon Stock 49,830 $0.00 $0.00
Disclosure

SEC source: 0000905148-26-002553 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,767

F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:11 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 184 $1.92 $353.28
Disclosure

SEC source: 0000905148-26-002501 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,937

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
April 17, 2026 Filed Apr 21, 2026 21:05 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 558 $1.78 $993.24
Disclosure

SEC source: 0000905148-26-001768 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,121

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:19 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 GrantStock Option (Right to Buy) · Derivative 129,760 $0.00 Strike: $1.51 $0.00
Disclosure

SEC source: 0000905148-26-001119 · form4.xml · derivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,760

Underlying: Common Stock · 129,760 shares

Expires 2036-02-29

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 21:12 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 217 $1.63 $353.71
Disclosure

SEC source: 0000905148-26-000937 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,679

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
January 17, 2026 Filed Jan 21, 2026 21:02 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 659 $1.98 $1,304.82
Disclosure

SEC source: 0000905148-26-000281 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,896

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
November 14, 2025 Filed Nov 18, 2025 21:32 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 184 $2.24 $412.16
Disclosure

SEC source: 0000905148-25-004130 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,555

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
October 17, 2025 Filed Oct 21, 2025 20:06 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 558 $1.81 $1,009.98
Disclosure

SEC source: 0000905148-25-003637 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,739

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 20:26 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 284 $1.81 $514.04
Disclosure

SEC source: 0000905148-25-003506 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,297

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
August 14, 2025 Filed Aug 18, 2025 21:18 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 184 $1.39 $255.76
Disclosure

SEC source: 0000905148-25-003042 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,581

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 20:28 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 558 $1.32 $736.56
Disclosure

SEC source: 0000905148-25-002493 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,765

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
May 14, 2025 Filed May 16, 2025 20:20 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 184 $1.14 $209.76
Disclosure

SEC source: 0000905148-25-001823 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,323

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
April 17, 2025 Filed Apr 18, 2025 19:51 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 558 $1.81 $1,009.98
Disclosure

SEC source: 0000905148-25-001257 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,507

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:32 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 GrantStock Option (Right to Buy) · Derivative 15,616 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0000905148-25-001076 · form4.xml · derivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,616

Underlying: Common Stock · 15,616 shares

Expires 2035-03-31

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on April 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 22:31 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 GrantStock Option (Right to Buy) · Derivative 93,693 $0.00 Strike: $5.31 $0.00
Disclosure

SEC source: 0000905148-25-000840 · form4.xml · derivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,693

Underlying: Common Stock · 93,693 shares

Expires 2035-02-28

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 21:59 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 217 $5.42 $1,176.14
Disclosure

SEC source: 0000905148-25-000729 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,065

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
January 17, 2025 Filed Jan 22, 2025 21:15 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 659 $5.78 $3,809.02
Disclosure

SEC source: 0000905148-25-000168 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,282

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
November 14, 2024 Filed Nov 18, 2024 21:31 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 184 $7.92 $1,457.28
Disclosure

SEC source: 0000905148-24-003227 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,941

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
October 17, 2024 Filed Oct 21, 2024 20:22 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 558 $7.87 $4,391.46
Disclosure

SEC source: 0000905148-24-002773 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,125

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
October 01, 2024 Filed Oct 3, 2024 22:49 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 284 $6.98 $1,982.32
Disclosure

SEC source: 0000905148-24-002637 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,683

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
August 14, 2024 Filed Aug 16, 2024 20:52 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 184 $7.02 $1,291.68
Disclosure

SEC source: 0000905148-24-002282 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,967

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 20:20 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 558 $7.69 $4,291.02
Disclosure

SEC source: 0001140361-24-033600 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,151

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
May 14, 2024 Filed May 16, 2024 23:03 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 184 $8.36 $1,538.24
Disclosure

SEC source: 0000905148-24-001493 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,709

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 20:10 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 558 $10.34 $5,769.72
Disclosure

SEC source: 0000905148-24-001186 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,893

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
March 01, 2024 Filed Nov 27, 2024 23:11 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 GrantStock Option (Right to Buy) · Derivative 67,567 $0.00 Strike: $5.70 $0.00
Disclosure

SEC source: 0000905148-24-003295 · form4.xml · derivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,567

Underlying: Common Stock · 67,567 shares

Expires 2034-02-28

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 22:14 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 217 $3.40 $737.80
Disclosure

SEC source: 0000905148-24-000765 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,451

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
January 17, 2024 Filed Jan 19, 2024 21:24 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 652 $4.35 $2,836.20
Disclosure

SEC source: 0000905148-24-000240 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,668

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
November 14, 2023 Filed Nov 17, 2023 00:43 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 735 $5.08 $3,733.80
Disclosure

SEC source: 0000905148-23-001477 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,320

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
October 17, 2023 Filed Oct 19, 2023 23:45 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 Tax withholdingCommon Stock 2,232 $5.48 $12,231.36
Disclosure

SEC source: 0000905148-23-001156 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,055

F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Read SEC document
September 26, 2023 Filed Sep 28, 2023 23:17 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 GrantStock Option (Right to Buy) · Derivative 11,576 $0.00 Strike: $8.95 $0.00
Disclosure

SEC source: 0000905148-23-001029 · form4.xml · derivative · entry 2

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,576

Underlying: Common Stock · 11,576 shares

Expires 2033-09-25

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2024, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
September 26, 2023 Filed Sep 28, 2023 23:17 UTC Acrivon Therapeutics, Inc. ACRV · Entity 573 GrantCommon Stock 3,858 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-001029 · form4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,287

F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) shall vest on October 1, 2024, and the remaining RSUs shall vest in three substantially equal annual installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
March 22, 2022 Filed Mar 24, 2022 21:12 UTC Butterfly Network, Inc. BFLY · Entity 4467 GrantClass A Common Stock 54,789 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-002943 · primarydocument.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,512

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 22, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:59 UTC Butterfly Network, Inc. BFLY · Entity 4467 GrantClass A Common Stock 189,655 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-031597 · tm228660d4_4.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,723

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 33% on March 4, 2023 with the remainder vesting in eight equal quarterly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date.

Read SEC document
February 16, 2022 Filed Feb 17, 2022 22:21 UTC Butterfly Network, Inc. BFLY · Entity 4467 SaleCommon Stock 16,677 $5.95 $99,253.17
Disclosure

SEC source: 0001562180-22-001584 · primarydocument.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · General Counsel & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,068

F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted on February 11, 2021 pursuant to a "sell to cover" provision included in the RSU Agreement.

F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $5.75 to $6.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
February 12, 2021 Filed Feb 17, 2021 02:04 UTC Butterfly Network, Inc. BFLY · Entity 4467 GrantStock Option (right to buy) · Derivative 259,575 Not disclosed Strike: $9.40 Not disclosed
Disclosure

SEC source: 0001104659-21-024563 · tm216719-20_4seq1.xml · derivative · entry 1

Miller Mary · CIK 0001841088 · GC and CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,575

Underlying: Class A Common Stock · 259,575 shares

Expires 2030-12-17

F2 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of November 19, 2020, by and among Longview Acquisition Corp. ("Longview"), Clay Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Longview ("Merger Sub"), and Butterfly Network, Inc., a Delaware corporation ("Butterfly"), pursuant to which Merger Sub merged with and into Butterfly, with Butterfly surviving as a wholly-owned subsidiary of Longview (which changed its name to "Butterfly Network, Inc.", the "Issuer"), this stock option was received in exchange for a stock option to acquire 250,000 shares of Butterfly common stock for $9.75 per share.

F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date.

Read SEC document
February 12, 2021 Filed Feb 25, 2021 21:05 UTC Amendment Butterfly Network, Inc. BFLY · Entity 4467 GrantStock Option (right to buy) · Derivative 259,575 Not disclosed Strike: $9.40 Not disclosed
Disclosure

SEC source: 0001104659-21-028226 · tm217907d1_4a.xml · derivative · entry 2

Miller Mary · CIK 0001841088 · GC and CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,575

Underlying: Class A Common Stock · 259,575 shares

Expires 2030-12-17

F4 · price: Received in connection with the Merger in exchange for a stock option to acquire 250,000 shares of Butterfly common stock for $9.75 per share.

F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to Ms. Miller's continued service through the applicable vesting date.

Read SEC document
February 12, 2021 Filed Feb 25, 2021 21:05 UTC Amendment Butterfly Network, Inc. BFLY · Entity 4467 GrantClass A Common Stock 155,745 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-21-028226 · tm217907d1_4a.xml · nonDerivative · entry 1

Miller Mary · CIK 0001841088 · GC and CS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,745

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over four years beginning on February 11, 2022, subject to Ms. Miller's continued service through the applicable vesting date.

F2 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of November 19, 2020, by and among Longview Acquisition Corp. ("Longview"), Clay Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Longview ("Merger Sub"), and Butterfly Network, Inc., a Delaware corporation ("Butterfly"), pursuant to which Merger Sub merged with and into Butterfly (the "Merger"), with Butterfly surviving as a wholly-owned subsidiary of Longview (which changed its name to "Butterfly Network, Inc.", the "Issuer"), these shares were received in exchange for 150,000 RSUs of Butterfly.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.